Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Gains from Investment Securities: 2023-2024

Historic Gains from Investment Securities for Upstream Bio (UPB) over the last 2 years, with Dec 2024 value amounting to $6.5 million.

  • Upstream Bio's Gains from Investment Securities rose 30.44% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 30.44%. This contributed to the annual value of $6.5 million for FY2024, which is 55.79% up from last year.
  • As of FY2024, Upstream Bio's Gains from Investment Securities stood at $6.5 million, which was up 55.79% from $4.2 million recorded in FY2023.
  • In the past 5 years, Upstream Bio's Gains from Investment Securities ranged from a high of $6.5 million in FY2024 and a low of $4.2 million during FY2023.
  • For the 2-year period, Upstream Bio's Gains from Investment Securities averaged around $5.3 million, with its median value being $5.3 million (2023).
  • Data for Upstream Bio's Gains from Investment Securities shows a peak YoY surged of 55.79% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Upstream Bio's Gains from Investment Securities stood at $4.2 million in 2023, then skyrocketed by 55.79% to $6.5 million in 2024.